

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: 21415-0012US1

Applicant: Judith Ann CLEMENTS Confirmation No. 9135
Appl. No.: 10/511,988 Art Unit: Unassigned
Filing Date: October 21, 2004 Examiner: Unassigned
Title: Method for Detecting the Presence of Risk of Prostate Cancer by
Detecting Products of PSA or KLK2

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56 and 37 CFR §1.97

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08A is a listing of documents known to applicant in order to comply with applicant's duty of disclosure pursuant to 37 C.F.R. §1.56 and §1.97. A copy of each of the listed documents is being submitted to comply with the provisions of 37 C.F.R. §1.97-1.99.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or is considered to be material to patentability as defined in 37 C.F.R. §1.56(b). Applicant does not waive any rights to take any action that would be appropriate to antedate or otherwise remove as a competent reference any document that is determined to be a *prima facie* prior art reference against the claims of the present application.

RELEVANCE

The foregoing documents came to the Applicant's attention during a search of the corresponding international application. A copy of the International Search Report setting forth the portion of each reference considered relevant by the examiner is attached.

TIMING/FEEES

The instant Information Disclosure Statement is being filed in compliance with 37 CFR §1.97(b) prior to the mailing date of the first official action, therefore, no fee is required in connection with its filing. However, the Commissioner is hereby authorized to charge any deficiency or to credit any overpayment to Deposit Account No. 08-1641.

Applicant respectfully requests that the listed documents be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08A be returned in accordance with M.P.E.P. §609.

Respectfully submitted,

Date: _____

7-5-05

By _____

[Signature] 33,75

HELLER EHRMAN LLP
1717 Rhode Island Avenue, NW
Washington, DC 20036
Telephone: (202) 912-2000
Facsimile: (202) 912-2020

[Signature] Paul M. Booth
Registration No. 40,244
Attorney for Applicants
Customer No. 26633

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	1	of	2
-------	---	----	---

Complete if Known

Application Number	10/511,988
Filing Date	October 21, 2004
First Named Inventor	Judith Ann CLEMENTS
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	21415-0012US1

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

**Examiner
Signature**

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete if Known	
		Application Number	10/511,988
		Filing Date	October 21, 2004
		First Named Inventor	Judith Ann CLEMENTS
		Group Art Unit	Unassigned
		Examiner Name	Unassigned
Sheet 2 of 2	Attorney Docket Number	21415-0012US1	

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	A04	National Cancer Institute – Cancer Facts http://cis.nci.nih.gov/fact/5_29.htm , September 18, 2000	
	A05	Compugen News & Events – Press Release – Compugen Discovers Novel Prostate-Specific Proteins Encoded by the PSA Gene”, February 13, 2002,	
	A06	ROSE DAHER et al., “Prostate-Specific Antigen and New Related Markers for Prostate Cancer”, Clin. Chem. Lab Med., 1998, pp. 671-681, Vol. 36, No. 9	
	A07	ROBERT K. NAM et al., “Serum Human Glandular Kallikrein-2 Protease Levels Predict the Presence of Prostate Cancer Among Men with Elevated Prostate-Specific Antigen”, Journal of Clinical Oncology, 2000, pp. 1036-1042, Vol. 18, No. 5	
	A08	ALICE YLIKOSKI et al, “Simultaneous Quantification of Human Glandular Kallikrein 2 and Prostate-Specific Antigen mRNAs in Peripheral Blood from Prostate Cancer Patients”, Journal of Molecular Diagnostics, August 2001, pp. 111-122, Vol. 3, No. 3	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.